Parsatuzumab

立即咨询

Parsatuzumab

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1312797-14-0

包装与价格：

包装	价格(元)
1mg	电议
5mg	电议

产品名称

Anti-EGFL7
RG 7414

产品介绍

Parsatuzumab (Anti-EGFL7; RG 7414) 是一种人源化单克隆抗体，作为免疫调节剂与EGFL7结合。Parsatuzumab 选择性阻断EGFL7与内皮细胞之间的相互作用，可能抑制血管再生，降低血管内皮生长因子 (VEGF) 抑制。

生物活性

Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducingvascular endothelial growth factor(VEGF) inhibition^[1].

IC₅₀& Target

VEGF; EGFL7^[1]

体外研究
(In Vitro)

EGFL7 is a vascular-restricted extracellular matrix protein that promotes endothelial cell adhesion and survival^[1].
Parsatuzumab (48 h) inhibits cell proliferation and increases apoptosis against patient-derived xenograft (PDX) cells^[2].

Cell Viability Assay^[2]

Cell Line:	Patient-derived xenograft (PDX) cells
Concentration:	/
Incubation Time:	48 hours
Result:	Inhibited cell proliferation by 70% from 20%, and resulted in apoptosis increases by 67-87% from 8-17%.

体内研究
(In Vivo)

Parsatuzumab (anti-EGFL7) enhances the antiangiogenesis, tumor growth control, and survival associated with antiVEGF monotherapy in several xenograft and genetically engineered murine tumor models^[1].
Parsatuzumab (50 mg/kg; i.v.; 3 times per week) targets EGFL7 and inhibits mantle cell lymphoma (MCL) cell growth and prolongs survival in mouse models of MCL^[2].

Animal Model:	NSG mice injected with Rec1 cells (s.c.)^[2]
Dosage:	50 mg/kg
Administration:	Intravenous injection; 3 times per week; sacrificed mice when tumor reached end point criteria
Result:	Significantly decreased tumor volume than IgG and increased survival of mice.

CAS 号

1312797-14-0

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.